VIVUS, Nordmark revise contract agreement for PANCREAZE development
Category: #health  By Paroma Bhattacharya  Date: 2019-06-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

VIVUS, Nordmark revise contract agreement for PANCREAZE development

California-headquartered biopharmaceutical firm VIVUS Inc. has recently announced an amendment to its contract manufacturing and supply agreement of delayed release capsules PANCREAZE® with Nordmark Arzneimittel GmbH & Co. KG.

Apparently, the revised treaty covers an initial term of 10 years followed by a renewal of additional five years. Financial terms of the agreement remained undisclosed.

Citing reliable sources, VIVUS and Nordmark will work together under the terms of the agreement to develop an advanced formulation of PANCREAZE, which is expected to enter the market by 2021, with the prime goal of extending its shelf life.

John Amos, Chief Executive Officer, VIVUS, was quoted saying that ensuring the supply of PANCREAZE to meet current and future demands of the drug at a predictable and stable price was their key strategy. He further added that with their current product formulations, there lies a bright future for PACREAZE market to create additional commercial and clinical value with the introduction of the product’s advanced formulations.

Nordmark CEO Jörn Tonne stated that their firm has managed to achieve considerable expertise in manufacturing PANCREAZE, and they look forward to extending their agreement with VIVUS. He also mentioned that they have had a successful record in developing new products to meet customer needs as well as the patients they serve.

Tonne noted that Nordmark plans to work with VIVUS in developing advanced formulations of PANCREAZE that make the drug even more convenient for patients diagnosed with exocrine pancreatic insufficiency.

For the record, PANCREAZE is a prescription drug used for treatment of patients who have difficulty digesting food normally because their pancreas, due to cystic fibrosis or other conditions, is unable to produce enough enzymes. PANCREAZE contains a mixture of digestive enzymes including amylases, proteases and lipases from pig pancreas, that helps body use up proteins, sugars and fats from food. The drug is effective and completely safe in children when taken in prescribed doses.

 

Source credit: https://www.nasdaq.com/press-release/vivus-and-nordmark-amend-contract-manufacturing-agreement-to-supply-current-and-future-demand-for-20190626-00835



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...